# PATENT ASSIGNMENT

# Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
Fucheng Qu	03/14/2013
Nathan Bryan Mantlo	03/14/2013

### **RECEIVING PARTY DATA**

Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
Internal Address:	Patent Division
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285

### PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13875314

# **CORRESPONDENCE DATA**

Fax Number: 3172763861

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: patents@lilly.com

Correspondent Name: Eli Lilly and Company

Address Line 1: P. O. Box 6288

Address Line 2: Patent Division

Address Line 4: Indianapolis, INDIANA 46206-6288

ATTORNEY DOCKET NUMBER:	X19604
NAME OF SUBMITTER:	Linda M. Durbin
Signature:	/Linda M. Durbin/
Date:	05/02/2013

502332688 REEL: 030334 FRAME: 0848

13875314

CH \$40.00

Total Attachments: 4

source=X19604AssignmentQu#page1.tif source=X19604AssignmentQu#page2.tif source=X19604AssignmentMantlo#page1.tif source=X19604AssignmentMantlo#page2.tif

Page 1 of 2 Docket No. X-19604

#### ASSIGNMENT

### WHEREAS, I

Fucheng QU, Carmel, Indiana 46033 Citizenship: CN

am an inventor/co-inventor of an invention that is the subject of a patent application ("Application") which is entitled *NOVEL PYRAZOLE COMPOUNDS*, for filing:

in the United States Patent and	Trademark Office on May 2, 2013
in the	on
and accorded Serial Number	,
in the Spanish Patent Office as and accorded Serial Number	a European Application on
with United States Patent and Trad-	under the Patent Cooperation Treaty ("PCT"), emark Office acting as Receiving Office on d Serial Number Pet US 2013/039164
	ander the Patent Cooperation Treaty ("PCT"), Confice (SIPO) of China acting as Receiving and accorded Serial Number
······································	
both of which claim the benefit of p filed May 10, 2012, and 61/769221	priority application Serial Numbers 61/645101, , filed February 26, 2013.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number(s) and filing date(s) for the application when it is known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application,

Page 2 of 2 Docket No. X-19604

inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

Date

Fucheng ØV

#### ASSIGNMENT

### WHEREAS, I

Nathan Bryan MANTLO, Brownsburg, Indiana 46112 Citizenship: US

am an inventor/co-inventor of an invention that is the subject of a patent application ("Application") which is entitled *NOVEL PYRAZOLE COMPOUNDS*, for filing:

in the United States Patent and accorded Serial Number	and Trademark Office on May 2, 2013
And the second s	on
in the Spanish Patent Office and accorded Serial Number	e as a European Application on,
with United States Patent and T	on under the Patent Cooperation Treaty ("PCT"), Trademark Office acting as Receiving Office on orded Serial Number PCT   US 2013   1039164
	on under the Patent Cooperation Treaty ("PCT"), erry Office (SIPO) of China acting as Receiving and accorded Serial Number
<u> </u>	
both of which claim the benefit filed May 10, 2012, and 61/769	of priority application Serial Numbers 61/645101, 221, filed February 26, 2013.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number(s) and filing date(s) for the application when it is known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application,

Page 2 of 2

inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

Nathan Bryan MANTLO